Sign in

CIK 0001737287

  • Non-accelerated filer
  • Smaller reporting company

Allogene Therapeutics, Inc.

Sign in to watch
Ticker
ALLO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
823562771
Phone
+1 650-457-2700
Business address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Derivatives Options or other derivatives
  2. 4 Grant or award Director acquired 16,498 shares (grant or award)
  3. 4 Grant or award Director acquired 16,498 shares (grant or award)
  4. 4 Exercise or conversion President and CEO acquired 27,410 shares (option exercise)
  5. 4 Exercise or conversion Chief Financial Officer acquired 14,897 shares (option exercise)
  6. 4 Exercise or conversion Director acquired 379,066 shares (option exercise)
  7. 4 Grant or award EVP of R&D and CMO acquired 200,534 shares (grant or award)
  8. 4 Open-market sale General Counsel sold 5,000 shares at $30.00 ($150,000)
  9. 4 Open-market sale General Counsel sold 5,000 shares at $28.30 ($141,476)
  10. 4 Open-market sale General Counsel sold 10,000 shares at an average $32.05 ($320,517)
  11. 4/A Gift President and CEO gave 411,556 shares (gift)
  12. 4 Grant or award Director acquired 53,635 shares (grant or award)
  13. 4 Grant or award President and CEO acquired 80,452 shares (grant or award)
  14. 4 Grant or award General Counsel acquired 22,202 shares (grant or award)
  15. 4 Grant or award Chief Technical Officer acquired 24,866 shares (grant or award)
  16. 4 Grant or award Chief Financial Officer acquired 24,866 shares (grant or award)
  17. 4 Grant or award EVP of R&D and CMO acquired 24,866 shares (grant or award)
  18. 4 Open-market sale EVP of R&D and CMO sold 2,798 shares at $38.05 ($106,471)
  19. 4 Open-market sale President and CEO sold 20,513 shares at $38.57 ($791,271)
  20. 4 Open-market sale Chief Technical Officer sold 6,164 shares at $38.14 ($235,089)

Page 9 of 14 · 275 filings